Specialization of tumour vasculature

By Erkki Ruoslahti. Nature Reviews. Cancer, 2002

718 citations recorded by the source corpus.

Subfields: Immunology and Allergy, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/1be6cebb7aa982f4ee9d1d56ba72623643e9c8f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology and Allergy

In Molecular Biology

In Oncology

Citations in the corpus

Hallmarks of cancer: the next generation. (2011, neutral): “Other avenues of research are revealing distinctive gene expression profiles of tumor-associated endothelial cells and identifying cell-surface markers displayed on the lumenal surfaces of normal versus tumor endothelial cells (Nagy et al., 2010; Ruoslahti et al., 2010; Ruoslahti, 2002).”
Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms (2004, background): “Moreover, tumor blood vessels and normal blood vessels are characterized by a distinct gene expression pattern, suggesting a distinct target profile when considering anti-angiogenic therapies (49, 50 ).”
A history of the study of solid tumour growth: The contribution of mathematical modelling (2004, background): “Motivated by the si gnificant experimental findings reported by Seftor et al. (1992) andAznavoorianet al.”
Photodynamic therapy for cancer (2003, background): “Another way to direct the photosensitizer to a certain cell type or compartment is to use specific targeting carriers, such as conjugated antibodies directed to tumour-associated antigens or vascular antigens, such as the ED-B domai”
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation (2010, background): “This could be a reasonable explanation for the discrepancy above mentioned [84].”
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance (2020, background): “Accumulating evidence has indicated that co-delivery of Bcl-2-targeted siRNA and chemotherapeutics by NPs is an alternative to overcoming drug resistance in cancer (Wang et al., 2006; Saad et al., 2008; Chen et al., 2009; Choi et al., 2019).”
Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. (2011, neutral): “1997); type 1 insulin-like growth factor receptor (IGF1R; Zhang & Yee 2000); VEGF receptor (Ruoslahti 2002), TGF-b receptor (Scaffidi et al.”
Magnetic nanoparticles in MR imaging and drug delivery. (2008, background): “A relatively large number of angiogenesis markers, which include the αvβ3 integrin, vascular endothelial growth factor (VEGF), cell surface nucleolin, and heparin sulfates, have been identified as potential targets for the delivery diagnostic and therapeutic agents [135,136].”
Tissue-penetrating delivery of compounds and nanoparticles into tumors (2009, neutral): “The RGD-directed integrins avb3, avb5, and a5b1 are upregulated in angiogenic endothelial cells and certain tumor cells (Eliceiri and Cheresh, 2001; Ruoslahti, 2002).”
Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium (2013, background): “Also, tumor neovasculature has been shown to overexpress markers such as certain integrins and prostatespecific antigens, which are nearly nonexistent on the normal vasculature surface (4, 9).”